Literature DB >> 11866886

[p16, p53 and c-erbB-2 gene expression in bladder carcinoma].

C Wang1, X Liu, L Wang, D Chen, Z Tan, Z Wang, T Chen.   

Abstract

OBJECTIVE: To investigate the expression of p16, p53 and c-erbB-2 proteins in bladder carcinoma and to analyze their correlation with tumor grade, clinic stage and metastasis.
METHODS: Immunohistochemical method was used to detect the p16, p53 and c-erbB-2 gene expressions in 75 cases of bladder carcinoma.
RESULTS: Positive rates of p16, p53 and c-erbB-2 in 75 cases of bladder cancer were 41.3%, 44.0% and 40.0%, respectively. p16 and c-erbB-2 gene expressions were related to the tumor grade and clinic stage (P < 0.05); p53 and c-erbB-2 gene expressions were related to the clinic stage and metastasis (P < 0.01). Oncogenes and/or antioncogenes altered expressions were found in 77.3% cases of bladder carcinoma, and oncogenes and/or antioncogenes with multiple altered expressions were found in 53.3% cases.
CONCLUSION: The analysis of multiple oncogene and/or antioncogene is more valuable than that of single oncogene and/or antioncogene. The altered expression of oncogene c-erbB-2 and antioncogenes p16 and p53 might play a promotive role in the tumorigenesis and development of bladder tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11866886

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  1 in total

Review 1.  Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xiaoning Gan; Xiaomiao Lin; Rongquan He; Xinggu Lin; Hanlin Wang; Liyan Yan; Hong Zhou; Hui Qin; Gang Chen
Journal:  Dis Markers       Date:  2016-04-20       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.